Orphan Drugs for Adults Market Report Spreads In 96 Pages with 133 Tables and Figures

Orphan Drugs for Adults Market 2023 : Highlights

The global Orphan Drugs for Adults market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Orphan Drugs for Adults is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Orphan Drugs for Adults is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Orphan Drugs for Adults in Hospital Pharmacies is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Orphan Drugs for Adults include Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc. In 2021, the world’s top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, Oncology Drugs, which accounted for % of the global market of Orphan Drugs for Adults in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

Top Key Players: